Aktiesnakken — Januar 2012
-
affitech købstilbud går ikke igennem
-
kun accept fra 30%
-
hvad med gn, bør den ikke stige
-
affitech købstilbud gennemføres ikke
-
fint af de ikke kunne få affitech for det beløb. Men havde faktisk troet at de ville hæve det lidt
-
http://borsen.dk/nyheder/politik/artikel/1/224351/eu_meget_taet_paa_aftale_om_graesk_gaeldssanering.html synes Miss M indikerede noget andet
-
lidt topsil news med købet af Cemat70 aktier, så er de måske nærmere et frasalg (paradoksalt nok)
-
ja repsac men jeg sidder i plus chatten
-
lidt nyt fra spectrum, måske det kan give lidt spekulation i topo på den korte bane
-
The Company Anticipates Filing Two New Drug Applications (NDAs) in 2012;
In Preparation of Potential Launch of Apaziquone and Belinostat in 2013, and to Bolster Worldwide ZEVALIN Sales, Spectrum Strengthens Commercial Team.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind